Filtered By:
Condition: Pneumonia
Management: WHO

This page shows you your search results in order of date.

Order by Relevance | Date

Total 432 results found since Jan 2013.

High flow nasal oxygen in frail COVID-19 patients hospitalized in intermediate care units and non-eligible to invasive mechanical ventilation
CONCLUSIONS: We suggest that HFNO is an option in non-ICU skilled units for older and frail patients with a severe COVID-19 pneumonia, otherwise non-suitable for intensive care and mechanical ventilation. Observation of clinical signs of respiratory failure before HFNO initiation was associated with mortality.PMID:37717386 | PMC:PMC10195878 | DOI:10.1016/j.resmer.2023.101026
Source: Respiratory Care - September 17, 2023 Category: Respiratory Medicine Authors: Corentin Meersseman Emmanuel Grolleau Nathalie Freymond Florent Wallet Thomas Gilbert Myriam Locatelli-Sanchez Laurence G érinière Emilie Perrot Pierre-Jean Souquet Clara Fontaine-Delaruelle Jean-St éphane David S ébastien Couraud Source Type: research

Characteristic analysis of adverse reactions of five anti-TNF ɑ agents: a descriptive analysis from WHO-VigiAccess
Conclusion: No causal associations could be established between the TNFα inhibitors and the ADRs. Current comparative observational studies of these inhibitors revealed common and specific adverse reactions in the ADR reports of the WHO received for these drugs. Clinicians should improve the rational use of these high-priced drugs according to the characteristics of ADRs.
Source: Frontiers in Pharmacology - July 24, 2023 Category: Drugs & Pharmacology Source Type: research

Dashboard With Bump Charts to Visualize the Changes in the Rankings of Leading Causes of Death According to Two Lists: National Population-Based Time-Series Cross-Sectional Study
CONCLUSIONS: A dashboard with bump charts can be used to improve the visualization of the changes in the rankings of leading CODs according to the WHO and NCHS lists as well as demographic characteristics; the visualization can help users make informed decisions regarding the most appropriate ranking list for their needs.PMID:37368475 | DOI:10.2196/42149
Source: Cancer Control - June 27, 2023 Category: Cancer & Oncology Authors: Shu-Yu Tai Ying-Chen Chi Yu-Wen Chien Ichiro Kawachi Tsung-Hsueh Lu Source Type: research

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
CONCLUSIONS: Combination LAMA+LABA therapy probably holds similar benefits to LABA+ICS for exacerbations and quality of life, as measured by the St George's Respiratory Questionnaire, for people with moderate to severe COPD, but offers a larger improvement in FEV1 and a slightly lower risk of pneumonia. There is little to no difference between LAMA+LABA and LAMA+ICS in the odds of having a serious adverse event. Whilst all-cause death may be lower with LABA+ICS, there was a very small number of events in the analysis, translating to a low absolute risk. Findings are based on moderate- to high-certainty evidence from hetero...
Source: Cochrane Database of Systematic Reviews - June 5, 2023 Category: General Medicine Authors: Nobuhiko Fukuda Nobuyuki Horita Ayami Kaneko Atsushi Goto Takeshi Kaneko Erika Ota Kayleigh M Kew Source Type: research

Identifying risk of death in children hospitalized with community-acquired pneumonia
CONCLUSION: The PREPARE tool with pulse oximetry showed good discriminatory ability on external validation in northern India. The tool can be used to assess risk of death of hospitalized children aged 2-59 months with community-acquired pneumonia for early referral to higher-level facilities.PMID:37008263 | PMC:PMC10042094 | DOI:10.2471/BLT.22.289000
Source: Bulletin of the World Health Organization - April 3, 2023 Category: International Medicine & Public Health Authors: Shally Awasthi Anuj Kumar Pandey Shambhavi Mishra CAP Study Group Source Type: research